GlassScriptPhysician profile
James K Mangan
NPI 1720107121
$61,173.14
in general payments reported to CMS, 2019-2025
19 companies · $18K in 2025
The $18K reported for 2025 was more than what 92% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,018 · 2020: $820 · 2021: $9,314 · 2022: $4,832 · 2023: $13K · 2024: $11K · 2025: $18K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $17K · Consulting Fee: $13K · Travel and Lodging: $5,207 · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $2,842 · Honoraria: $2,740 · Food and Beverage: $1,047.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $16,903.50 |
| Consulting Fee | $13,450.00 |
| Travel and Lodging | $5,206.67 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $2,841.78 |
| Honoraria | $2,740.00 |
| Food and Beverage | $1,047.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $21,745.87 | 2020-2025 | Xospata |
| Acceleron Pharma, INC. | $7,009.84 | 2021 | |
| Syndax Pharmaceuticals, INC. | $5,614.10 | 2025 | Revuforj |
| Gilead Sciences, INC. | $4,859.62 | 2023 | |
| Daiichi Sankyo INC. | $4,743.28 | 2024-2025 | Vanflyta |
| Agios Pharmaceuticals, INC. | $4,017.65 | 2019 | |
| Rigel Pharmaceuticals, INC. | $3,456.38 | 2023 | Rezlidhia, Tavalisse |
| Jazz Pharmaceuticals INC. | $2,480.00 | 2023 | Rylaze |
| Pfizer INC. | $2,250.00 | 2021 | |
| Celgene Corporation | $2,076.00 | 2022 | |
| Cti Biopharma Corp. | $1,725.00 | 2023 | Vonjo |
| Astrazeneca Pharmaceuticals LP | $682.00 | 2025 | |
| Taiho Oncology, INC. | $434.78 | 2025 | |
| Abbvie INC. | $54.29 | 2021 | |
| Abbott Laboratories | $24.33 | 2025 | Octrode |
4 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Mangan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.